| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Djalonensone-d3 does not have a specific biological target for its use as a labeled compound. Its primary function is as a stable isotope-labeled standard for pharmacokinetic, metabolic, and bioavailability studies.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as tracers that influence measurement during the drug development process. It's possible that the pharmacokinetics and functional range of medications contribute to the concern over mutagenesis [1].
The compound is not evaluated for traditional in vitro biological activity. Its "activity" is as an analytical standard enabling accurate quantification and tracking of Djalonensone in complex biological matrices. It is used in natural product profiling and drug discovery research. |
| ln Vivo |
No in vivo activity is applicable for Djalonensone-d3, as it is not a therapeutic agent. Its use is confined to the laboratory for pharmacokinetic and metabolic studies. The compound is not administered to living organisms for any biological effect.
|
| Enzyme Assay |
The compound is used as an analytical standard in pharmacokinetic, metabolic, and bioavailability studies. Its performance is assessed by its ability to provide accurate and precise quantification of Djalonensone in complex biological matrices using mass spectrometry.
|
| Cell Assay |
Djalonensone-d3 is not used in standard cell culture for pharmacological studies. It is a chemical reagent used in analytical chemistry for natural product profiling and drug discovery research. Its isotopic labeling allows for precise measurement of Djalonensone levels.
|
| Animal Protocol |
Animal studies are not conducted with Djalonensone-d3 as an active compound. It is used as an analytical standard in pharmacokinetic and metabolic studies in animals. The compound is never administered to animals for therapeutic or investigative purposes.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not relevant for Djalonensone-d3, as it is not a therapeutic agent. Its chemical properties include a molecular weight of 275.27 g/mol and a molecular formula of C15H9D3O5. The compound has a purity of >98% and should be stored at -20°C in powder form for up to 3 years.
|
| Toxicity/Toxicokinetics |
Toxicological data for Djalonensone-d3 are not extensively detailed, as it is a research compound. It is not intended for human or veterinary use. Standard laboratory safety precautions, including the use of personal protective equipment (PPE), should be followed when handling the compound.
|
| References | |
| Additional Infomation |
Djalonensone-d3 is a research-grade compound used as an analytical standard for pharmacokinetic, metabolic, and bioavailability studies. Its stable isotope labeling enhances analytical accuracy in complex biological matrices. The compound is not approved for therapeutic use and is strictly for laboratory research.
|
| Molecular Formula |
C15H12O5
|
|---|---|
| Molecular Weight |
275.271269798279
|
| Exact Mass |
275.087
|
| CAS # |
2468774-90-3
|
| Related CAS # |
Djalonensone;23452-05-3
|
| PubChem CID |
145875000
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.2
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
20
|
| Complexity |
385
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C(C2C(=CC(=CC=2C2C(C)=CC(=CC1=2)O)OC([2H])([2H])[2H])O)=O
|
| InChi Key |
LCSDQFNUYFTXMT-BMSJAHLVSA-N
|
| InChi Code |
InChI=1S/C15H12O5/c1-7-3-8(16)4-12-13(7)10-5-9(19-2)6-11(17)14(10)15(18)20-12/h3-6,16-17H,1-2H3/i2D3
|
| Chemical Name |
3,7-dihydroxy-1-methyl-9-(trideuteriomethoxy)benzo[c]chromen-6-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6328 mL | 18.1640 mL | 36.3280 mL | |
| 5 mM | 0.7266 mL | 3.6328 mL | 7.2656 mL | |
| 10 mM | 0.3633 mL | 1.8164 mL | 3.6328 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
